Jinan Babio Biotechnology Co., Ltd. was established in 2003 and is a high-tech enterprise specializing in the research, development, production and sales of in vitro diagnostic reagents. The company was successfully listed on the New OTC Market in 2014 (stock name: BioBio, stock code: 830774). The company has established a strict quality management system and passed the ISO9001:2008 and ISO13485:2003 international quality system certification. The company has internationally advanced fully automatic production equipment and standard pharmaceutical-grade purification workshops. Baibo Biotechnology is strong, currently owns more than 72 independent intellectual property rights, undertakes a number of national-level scientific research projects, and has 91 medical device registration certificates approved by the State Food and Drug Administration. The company's products mainly involve virus sampling,
rapid detection kits, microbial detection reagents, POCT detection reagents, biochemical diagnostic reagents, diagnostic equipment, etc. The end of the Covid-19 pandemic. With an outbreak around the world in 2020, Barium Double O has actively participated in R&D and its manufacturing of Covid-19 sampling and testing reagents. At present, the company's
virus transport medium, nasal/oral sampling
swab products and product quality have been recognized by medical institutions and laboratories in various countries. In the future, Babio will be committed to providing better technologies and services to continue to contribute to human health. struggle.